About Shelter
Shelter is a publicly listed company based in Ahmedabad (India) founded in 1965 by Mustaqim Sabugar. Shelter is recognized as a trusted manufacturer of human and veterinary healthcare medicines in India. It operates on a Direct-to-Consumer (D2C), B2B2C, and HealthTech model. Its Indian entity Shelter Pharma Limited reported revenue of ₹73.15 Cr. Shelter offers products and services including Sherolax Tablets, Diabetone Tablet, Gasoshel Tablet, and Purgovet Bolus. Its focus areas include Pharmaceuticals and Herbal Medicine.
Company details
Shelter, established in 1965, is engaged in the production of herbal remedies for human and veterinary healthcare. The company operates within the pharmaceutical sector, focusing on natural healing solutions that blend traditional Ayurvedic principles with modern scientific validation. Products are developed for diverse health needs, including digestive, diabetic, and reproductive health issues. With a presence in over 10 countries across the Middle East, Southeast Asia, and Africa, Shelter ensures international quality standards through state-of-the-art manufacturing and rigorous quality control. The mission is centered on providing safe, superior, and cost-effective natural remedies through continuous research and education.
- Headquarters Ahmedabad, India
- Founders Mustaqim Sabugar
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website shelter.co.in
- Social LinkedIn X Facebook Instagram
- Legal Name Shelter Pharma Ltd.
- Market Cap₹75.77 Cr
SHELTER · BSE
- Share Price₹45.00
-2.62% today
- Revenue₹73.13 Cr
FY 2025-26 · +44.4% YoY
- EBITDA₹12.74 Cr
Margin 17.4%
- Net Profit₹9.03 Cr
FY 2025-26 · +24.6% YoY
- P/E (TTM)8.8x
P/B 1.1x
Associated legal entities of Shelter
Shelter operates through Shelter Pharma Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Shelter Pharma Limited Listed CIN L24233GJ2007PLC051956 | Active | 12 Oct 2007 | Himatnagar, Gujarat | ₹73.2 Cr | 6 | 8 | View details |
Products & Services of Shelter
Shelter offers a comprehensive portfolio of products and services, including Sherolax Tablets, Diabetone Tablet, Gasoshel Tablet, and Purgovet Bolus.
Constipation is corrected by softening stool and enhancing mobility.
Blood sugar levels are managed with herbal diabetic support.
Digestive issues like gas and acidity are effectively relieved.
Bowel evacuation in animals is supported with purgative action.
Board of directors of Shelter Pharma Limited (Shelter)
Shelter Pharma Limited is the primary company behind Shelter. The board of Shelter Pharma Limited currently have 6 directors; the longest-serving is Shakil Nisarahmed Sabugar, appointed in 2007. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shakil Nisarahmed Sabugar DIN 01474868 | Whole-time director | 12 Oct 2007 | 19 yrs | Shelter Pharma Limited |
| Mustaqim Nisarahmed Sabugar DIN 01456841 | Managing Director | 12 Oct 2007 | 19 yrs | Shelter Pharma Limited |
| Parvezbanu Mohamed Rafiq Idariya DIN 01470286 | Director | 13 Oct 2021 | 5 yrs | Shelter Pharma Limited |
| Mosinkhan Gafarkhan Pathan DIN 10039962 | Director | 23 Feb 2023 | 3 yrs 8 mo | Shelter Pharma Limited |
| Riyazahmed Abdulrauf Sabugar DIN 10039965 | Director | 23 Feb 2023 | 3 yrs 8 mo | Shelter Pharma Limited |
| Vinita Shivraj Gadhavi DIN 09102407 | Director | 31 Jul 2026 | 3 mo | Shelter Pharma Limited |
People of Shelter
1 people are tracked at Shelter (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder | Leadership |
Complete people profiles for Shelter
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Shelter
Shelter is a publicly listed company on the BSE with ticker symbol SHELTER in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date23 Aug 2023
- Listed onBSE: 543963
- Listed entityShelter Pharma Ltd.
- Exchange sectorHealth technology
- ISININE013V01011
- Share price₹50.71 (-4.97% on the day) · 2026-10-14
- Volume (last session)33,000
Financials of Shelter
Exchange-reported figures of Shelter Pharma Limited, the listed company behind Shelter (BSE: SHELTER).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 73.13 | 50.66 | 40.02 | 36.15 | 30.06 | 22.48 | 30.07 |
| Revenue growth | +44.4% | +26.6% | +10.7% | +20.3% | +33.7% | -25.2% | - |
| EBITDA | 12.74 | 10.08 | 8.77 | 7.17 | 3.06 | 0.17 | 0.25 |
| EBITDA margin | +17.4% | +19.9% | +21.9% | +19.8% | +10.2% | +0.8% | +0.8% |
| Profit before tax | 12.23 | 9.69 | 8.26 | 6.98 | 2.81 | 0.04 | 0.12 |
| Net profit | 9.03 | 7.25 | 6.18 | 5.92 | 2.06 | 0.02 | 0.09 |
| Net profit margin | +12.4% | +14.3% | +15.4% | +16.4% | +6.9% | +0.1% | +0.3% |
| EPS (₹) | 5.43 | 6.26 | 5.36 | 6.72 | 42.54 | 0.85 | 1.77 |
| Balance sheet | |||||||
| Total assets | 77.50 | 43.82 | 36.44 | 16.38 | 8.97 | 7.20 | 7.30 |
| Net worth | 76.63 | 42.72 | 35.82 | 14.55 | 8.80 | 7.11 | 6.98 |
| Total debt | 0.80 | 1.04 | 0.58 | 1.78 | 0.13 | 0.00 | 0.24 |
| Cash & bank | 1.08 | 3.42 | 5.04 | 0.43 | 0.10 | 0.37 | 0.14 |
| Net working capital | 48.33 | 28.76 | 28.24 | 13.77 | 6.06 | 4.98 | 4.84 |
| Cash flow | |||||||
| Cash from operations | (12.48) | 5.42 | (1.96) | 0.00 | 0.52 | (0.28) | (0.27) |
| Cash from investing | (14.55) | (7.13) | (4.43) | 0.11 | (0.85) | 0.03 | 0.29 |
| Cash from financing | 24.69 | 0.09 | 11.01 | 0.21 | 0.06 | 0.48 | 0.00 |
Financial Statements
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 73.13 | 50.66 | 40.02 | 36.15 | 30.06 | 22.48 | 30.07 |
| Revenue growth | +44.4% | +26.6% | +10.7% | +20.3% | +33.7% | -25.2% | - |
| Other income | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Total expenses | 60.39 | 40.58 | 31.25 | 28.98 | 27.00 | 22.31 | 29.82 |
| Employee cost | 1.13 | 1.22 | 0.63 | 0.45 | 0.35 | 0.33 | 0.39 |
| EBITDA | 12.74 | 10.08 | 8.77 | 7.17 | 3.06 | 0.17 | 0.25 |
| EBITDA margin | +17.4% | +19.9% | +21.9% | +19.8% | +10.2% | +0.8% | +0.8% |
| Depreciation | 0.41 | 0.27 | 0.25 | 0.16 | 0.17 | 0.12 | 0.13 |
| Interest | 0.12 | 0.13 | 0.26 | 0.03 | 0.08 | 0.02 | 0.01 |
| Profit before tax | 12.23 | 9.69 | 8.26 | 6.98 | 2.81 | 0.04 | 0.12 |
| Tax | 3.20 | 2.44 | 2.08 | 1.78 | 0.75 | 0.02 | 0.03 |
| Net profit | 9.03 | 7.25 | 6.18 | 5.92 | 2.06 | 0.02 | 0.09 |
| Net profit margin | +12.4% | +14.3% | +15.4% | +16.4% | +6.9% | +0.1% | +0.3% |
| EPS (₹) | 5.43 | 6.26 | 5.36 | 6.72 | 42.54 | 0.85 | 1.77 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 16.61 | 11.56 | 11.56 | 7.74 | 0.48 | 0.48 | 0.45 |
| Reserves & surplus | 56.05 | 31.16 | 24.26 | 6.81 | 8.32 | 6.63 | 6.53 |
| Shareholders' funds (net worth) | 76.63 | 42.72 | 35.82 | 14.55 | 8.80 | 7.11 | 6.98 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.80 | 1.04 | 0.58 | 1.78 | 0.13 | 0.00 | 0.24 |
| Total debt | 0.80 | 1.04 | 0.58 | 1.78 | 0.13 | 0.00 | 0.24 |
| Total liabilities | 77.50 | 43.82 | 36.44 | 16.38 | 8.97 | 7.20 | 7.30 |
| Assets | |||||||
| Gross block | 9.94 | 8.36 | 6.38 | 4.40 | 3.17 | 3.12 | 3.11 |
| Net block | 7.14 | 5.97 | 4.25 | 2.52 | 1.45 | 1.57 | 1.77 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.55 | 0.00 | 0.00 |
| Investments | 0.68 | 0.68 | 0.00 | 0.00 | 0.68 | 0.68 | 0.68 |
| Inventories | 24.44 | 12.90 | 9.93 | 7.96 | 5.67 | 4.02 | 4.31 |
| Sundry debtors | 11.81 | 9.47 | 8.85 | 8.19 | 1.61 | 0.76 | 0.61 |
| Cash & bank balances | 1.08 | 3.42 | 5.04 | 0.43 | 0.10 | 0.37 | 0.14 |
| Loans & advances | 17.73 | 7.49 | 5.90 | 2.13 | 2.45 | 2.73 | 3.01 |
| Total current assets | 55.06 | 33.28 | 29.72 | 18.71 | 9.83 | 7.88 | 8.07 |
| Total current liabilities | 6.73 | 4.52 | 1.48 | 4.94 | 3.77 | 2.90 | 3.23 |
| Net working capital | 48.33 | 28.76 | 28.24 | 13.77 | 6.06 | 4.98 | 4.84 |
| Total assets | 77.50 | 43.82 | 36.44 | 16.38 | 8.97 | 7.20 | 7.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.42 | 5.04 | 0.43 | 0.10 | 0.37 | 0.14 | 0.12 |
| Net cash from operating activities | (12.48) | 5.42 | (1.96) | 0.00 | 0.52 | (0.28) | (0.27) |
| Net cash from investing activities | (14.55) | (7.13) | (4.43) | 0.11 | (0.85) | 0.03 | 0.29 |
| Net cash from financing activities | 24.69 | 0.09 | 11.01 | 0.21 | 0.06 | 0.48 | 0.00 |
| Net change in cash | (2.34) | (1.62) | 4.61 | 0.33 | (0.27) | 0.23 | 0.02 |
| Closing cash | 1.08 | 3.42 | 5.04 | 0.43 | 0.10 | 0.37 | 0.14 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +44.4% | +26.6% | +10.7% | +20.3% | +33.7% | -25.2% | - |
| EBITDA growth | +26.4% | +14.9% | +22.3% | +134.3% | +1700.0% | -32.0% | - |
| PBT growth | +26.2% | +17.3% | +18.3% | +148.4% | +6925.0% | -66.7% | +71.4% |
| Net income growth | +24.6% | +17.3% | +4.4% | +187.4% | - | -77.8% | - |
| Revenue CAGR (3Y) | +26.5% | +19.0% | +21.2% | +6.3% | +0.1% | -7.2% | - |
| EBITDA CAGR (3Y) | +21.1% | +48.8% | +272.3% | +206.1% | - | +4.3% | - |
| Profitability & leverage | |||||||
| Net income margin | +12.4% | +14.3% | +15.4% | +14.4% | +6.9% | +0.1% | +0.3% |
| Return on capital employed | - | +25.0% | +33.5% | +68.1% | +40.5% | +1.3% | +1.9% |
| Return on net worth | - | +18.9% | +25.6% | +55.3% | +29.4% | +0.7% | +1.4% |
| Debt / equity | - | 0.02 | 0.05 | 0.09 | 0.01 | 0.02 | 0.04 |
| Long-term debt / equity | - | 0.02 | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.97 | 1.33 | 3.05 | 0.43 | 2.77 | 40.00 | 8.33 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 7.88 | 8.99 | 12.71 | 13.63 | 10.55 | 14.46 |
| Inventory turnover | - | 4.44 | 4.47 | 5.30 | 6.20 | 5.40 | 6.98 |
| Debtors turnover | - | 5.53 | 4.70 | 7.38 | 25.37 | 32.82 | 49.30 |
| EPS (₹) | 5.43 | 6.26 | 5.36 | 6.72 | 42.54 | 0.85 | 1.77 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 43.18 | 36.14 | 30.17 | 17.57 | 162.45 | 127.48 | 131.03 |
Web traffic of Shelter
The website of Shelter (shelter.co.in) receives about 1.8K visits a month.
- Monthly visits1.8K
▼ 9% vs previous month
Websites whose visitors overlap most with Shelter. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
merrilpharma.com | merrilpharma.com | 100% | – | ||
| nabros.in | 97% | View details | |||
| baroquepharma.com | 96% | View details | |||
utkarshayurveda.co.in | utkarshayurveda.co.in | 95% | #14,337,854 | – | |
| jinst.in | 95% | #10,474,871 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for Shelter
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Alternative Medicine Products
3 companies that operate in the same segment as Shelter (Alternative Medicine Products) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Homeopathic medicine manufacturing and online retail in India. | 1898 | Noida, Uttar Pradesh, India | USD 26.35 M | 1,192 | ||
Operates an online store specializing in ayurvedic and homeopathic medicines. | 2016 | Delhi, Delhi, India | USD 1.25 M | 16 | ||
Offers Ayurvedic treatments, consultations, and products for various diseases and wellness. | 1992 | Faridabad, Haryana, India | USD 10.08 M | 570 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Shelter
Complete news archive for Shelter
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Shelter
Shelter was founded in 1965.
Shelter is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
The primary company behind Shelter, Shelter Pharma Limited, reported revenue of ₹73.15 Cr for FY 2026, up 44% year on year.
Shelter, established in 1965, is engaged in the production of herbal remedies for human and veterinary healthcare. The company operates within the pharmaceutical sector, focusing on natural healing solutions that blend traditional Ayurvedic principles with modern scientific validation. Products are developed for diverse health needs, including digestive, diabetic, and reproductive health issues. With a presence in over 10 countries across the Middle East, Southeast Asia, and Africa, Shelter ensures international quality standards through state-of-the-art manufacturing and rigorous quality control. The mission is centered on providing safe, superior, and cost-effective natural remedies through continuous research and education.
Shelter offers Sherolax Tablets, Diabetone Tablet, Gasoshel Tablet, and Purgovet Bolus.
Yes, Shelter is publicly traded on BSE under the ticker symbol SHELTER.
Shelter operates through Shelter Pharma Limited.
The legal entities of Shelter currently have 8 directors, including Parvezbanu Mohamed Rafiq Idariya, Mohammedrafiq Gulamnabi Shaikh, Shakil Nisarahmed Sabugar and others.